OFIX icon

Orthofix Medical

14.53 USD
+0.03
0.21%
Updated Aug 26, 3:22 PM EDT
1 day
0.21%
5 days
-0.07%
1 month
27.46%
3 months
26.46%
6 months
-15.82%
Year to date
-15.82%
1 year
-16.11%
5 years
-52.01%
10 years
-60.91%
 

About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Employees: 1,616

0
Funds holding %
of 7,433 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

112% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 33

6.48% more ownership

Funds ownership: 85.05% [Q1] → 91.53% (+6.48%) [Q2]

0% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 27

2% less funds holding

Funds holding: 159 [Q1] → 156 (-3) [Q2]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]

26% less capital invested

Capital invested by funds: $541M [Q1] → $400M (-$141M) [Q2]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $24K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
10%
upside
Avg. target
$16
10%
upside
High target
$16
10%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Barrington Research
Michael Petusky
10%upside
$16
Outperform
Initiated
23 Jun 2025

Financial journalist opinion

Based on 5 articles about OFIX published over the past 30 days

Positive
Zacks Investment Research
2 weeks ago
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity right now?
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
Neutral
The Motley Fool
2 weeks ago
Orthofix (OFIX) Q2 Revenue Rises 2%
Orthofix (OFIX) Q2 Revenue Rises 2%
Orthofix (OFIX) Q2 Revenue Rises 2%
Neutral
Seeking Alpha
3 weeks ago
Orthofix Medical Inc. (OFIX) Q2 2025 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Julie B. Andrews - Chief Financial Officer Julie D.
Orthofix Medical Inc. (OFIX) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
3 weeks ago
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago.
Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates
Neutral
Business Wire
3 weeks ago
Orthofix Reports Second Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and l.
Orthofix Reports Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 13, 2025 at 9:00 am Eastern Time. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix Investor Relations Website at ir.or.
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
Neutral
Business Wire
1 month ago
Orthofix to Report Second Quarter 2025 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing.
Orthofix to Report Second Quarter 2025 Financial Results
Neutral
Business Wire
2 months ago
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate represents the first commercially available device in the U.S. with a patented design for use in the TBT procedure to provide a limb preservation treatment option for addressing bony or soft tissue deformities or defects, such as diabetic ulcers. “I have b.
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
Neutral
Seeking Alpha
3 months ago
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Caitlin Cronin - Canaccord Genuity Jeffrey Cohen - Ladenburg Operator Thank you for standing by. My name is Tina, and I will be your conference operator today.
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
Orthofix (OFIX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™